SAN DIEGO--(BUSINESS WIRE)--Retrophin, Inc. (NASDAQ:RTRX) today announced the closing of the agreement to sell its Rare Pediatric Disease Priority Review Voucher to Sanofi (EURONEXT: SAN and NYSE: SNY). Under the terms of the agreement, Retrophin has received a payment of $150 million, and will receive two additional payments of $47.5 million in 2016 and 2017.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
